Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23-Reference-Cited by-同舟云学术

Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23

Published:2017 Issue:10 Volume:64 Page:1033-1039
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Hana Taijun¹,Tanaka Shota¹,Nakatomi Hirofumi¹,Shojima Masaaki¹,Fukumoto Seiji²,Ikemura Masako³,Saito Nobuhito¹

Affiliation:

1. Department of Neurosurgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan

2. Department of Endocrinology, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan

3. Department of Pathology, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/64/10/64_EJ17-0177/_pdf

Reference24 articles.

1. 1. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, et al. (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28: 1-30.

2. 2. Hori M, Shimizu Y, Fukumoto S (2011) Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152: 4-10.

3. 3. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505.

4. 4. Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, et al. (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62: 811-816.

5. 5. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphopenic osteomalacia of tumor genesis under mask of ankylosing spondylitis;The Clinician;2024-09-01

2. Intracranial Phosphaturic Mesenchymal Tumors: A Systematic Literature Review of a Rare Entity;World Neurosurgery;2024-07

3. 18F-AlF-NOTA-octreotide PET/CT in the localization of tumor-induced osteomalacia: case series and literature review;Frontiers in Endocrinology;2024-06-03

4. Phosphaturic mesenchymal tumor with de novo liver metastases: a case report and literature review;Therapeutic Advances in Medical Oncology;2024-01

5. Occipital bone and tumor-induced osteomalacia: a rare tumor site for an uncommon paraneoplastic syndrome;Archives of Osteoporosis;2023-07-12